Reverse mergers, takeovers, tender offers and other control changes at public biotech companies, newest first.
Mergers ·
Holders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.
INMA meeting room with a long table and a screen. CC0, via rawpixel
Mergers
Rallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.
RLYB
Mergers
Redx holders would own about 59.74% of the combined company and Skye holders about 5.38%, at an assumed exchange ratio of 0.0892. Skye also plans a reverse stock split, and its proxy warns that stockholders will vote without certainty about the combined company's Nasdaq listing.
SKYE
Mergers
Bolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028.
BOLT
Mergers
J.P. Morgan counted 27 reverse mergers worth $7.5 billion in the first nine months of 2026. Nineteen came with private placements, against three of 12 in 2025.
The all-cash deal values Silence at about $1.1 billion in enterprise value, an 82% premium to its 30-day average price. Closing is expected in the first quarter of 2027.
SLNThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
MDXGThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
MDXGRallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.
RLYBAditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.
ADTXAibotics signed an asset purchase agreement with PlayJamaica Limited on October 12, 2026, and completed the acquisition on October 14, issuing 22,500 shares of Series B Preferred Stock.
AIBTMilestones could add up to $47.5 million, plus royalties at a mid-teens percentage of net sales. The product has tentative FDA approval only, and Aquestive will be its exclusive manufacturer under a 20-year supply agreement.
ETONThe merger with Langham Merger Sub took effect on October 13, 2026, and LogicMark is now a wholly owned subsidiary of Langham Project LLC.
LGMKPulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026.
PULMSenti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025.
SNTIAlaunos bought Velaris in a stock deal and closed a $350 million private placement led by Fairmount. Velaris has no product candidate tested in humans, and Alaunos had $124,000 in cash at June 30, 2026, according to its quarterly report.
TCRTThe amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9.
PASGBoundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company.
BOLDViatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price.
PCRXVTRSJasper Therapeutics will pay $0.324 in cash per warrant for up to 12,345,707 warrants, about $4.0 million if all are tendered, and the offer runs until November 6, 2026.
JSPRThe purchase closed October 6, 2026 for $2,000,000 in cash and 25,000,000 shares, and four directors have ties to the seller's group.
HEPAThe buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units.
ADIABeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work.
BYSIBeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics.
BYSIThe October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.
NDRAThe cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan.
SGP4536BLCOTwo strategic investors paid the first $1.75 million tranche for a 17.5% interest in MangoRx IP, a former subsidiary of Mangoceuticals. The other $750,000, for 7.5%, is due by November 28, 2026, and the company's cash had fallen to $228,688 by June 30.
MGRXA technical amendment sets a formula-based exchange ratio for a combined company of 10,000,000 shares. A later amendment cut that number to 5,000,000.
CMMBLexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed.
LXEOThe deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share.
LFCRIn a strategic update dated September 23, 2026, Glucotrack and Lokahi Therapeutics said LT-100 is the immediate priority, with a clinical protocol submitted for regulatory review.
GCTKZymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative.
ZYMEZoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.
IBOPRPHThe deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027.
AEMDTarsus paid $270,000,000 in cash and issued 2,908,692 shares at closing. Up to $350,000,000 in milestones and tiered revenue sharing on gildeuretinol sales remain to be paid.
TARSClearmind will also lend Charging Robotics $1.5 million at 4% as a condition of closing, which is expected the week of September 7, 2026.
CMNDThe sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect.
ISCOShareholders backed the Korsana merger share issuance and change of control on August 26, 2026. The combined company expects to trade on Nasdaq as KRSA from September 9, 2026; a Cayman redomestication failed.
KRSAThe August 17, 2026 closing leaves the price open to an inventory adjustment and up to $3 million in contingent payments. Elutia says it will focus on NXT-41x and believes it has funding through the first full year of its commercial launch in 2028.
ELUTArbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first.
ABUSENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026.
NDRAASPIFulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers.
FULCNet loss was $0.4 million for the quarter ended June 30, 2026, while the company advances a share exchange that would make Future NRG Sdn. Bhd. a wholly owned subsidiary.
BGMSEnsysce completed its acquisition of Cy Biopharma on August 5, 2026 and agreed to a Series C private placement of about $43 million in two tranches. After the deal, Cy's former holders would own about 73.86% of Ensysce on a fully diluted basis, and the second tranche depends on a clinical milestone.
ENSCEton (Nasdaq: ETON) signed a license agreement for ASN-001, a late-stage infantile hemangioma gel. It owes milestone payments after FDA approval and tiered royalties of 10% to 15% on net sales.
ETONThe agreement dated July 31, 2026 would convert LogicMark into a wholly owned subsidiary of Langham Project, LLC, subject to a shareholder vote and other conditions.
LGMKThe combined company would operate as Caldera Therapeutics. A concurrent private placement of approximately $278 million is expected to close alongside the merger, which is expected to close by early 2027.
SYBXProcessa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million.
PCSAThe board of The Greater Cannabis Company, Inc. named Carlos Septién, Michelle Cervantes Vivanco and Ernesto Gómez Berjón on July 29, 2026, and they join the board after a notice period.
GCANDScancell will acquire Neuphoria in an all-share deal that would create a combined company listed on Nasdaq, alongside a financing of up to $89 million.
NEUPSCLPSenti Biosciences agreed on July 14, 2026 to move most of its business, including lead candidate SENTI-202, to an affiliate of its largest stockholder. Holders would receive contingent value rights worth up to $60 million that pay only if milestones are met, while the company used $43.4 million in operations in 2025.
SNTINextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name.
NXTCMatinas BioPharma agreed to combine with GH Power in a business combination expected to close in the fourth quarter of 2026, and to sell its MAT2203 and LNC business to Azurity Pharmaceuticals for $4.0 million upfront.
MTNBBora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments.
MGNXBora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received.
MGNXLIXTE is issuing 2,992,041 common shares and 50,366.07 Series D preferred shares to NOMAD stockholders, and has changed its name to NOMAD Power Solutions effective July 3, 2026.
NMADCumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold.
CPIXApotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs.
CPIXZymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note.
ZYMEThe license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million.
RIGLRigel paid the licensors a one-time upfront payment of $70.0 million after the antitrust waiting period ended early. The 8-K describes no milestones, royalties or clinical details for the drug.
RIGLPrestige Consumer Healthcare (NYSE: PBH) completed the Breathe Right purchase for $1.045 billion in cash and entered a Term Loan Credit Agreement. It also raised its asset-based revolver commitments to $225 million.
PBHRocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028.
RCKTThe deal adds AT177, a colon-targeted AhR agonist for ulcerative colitis, to Adial's pipeline, with about $32 million in initial gross proceeds and up to $32 million more tied to Phase 1 initiation.
ADILVeraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million.
VRXAAditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.
ADTXA Business Combination Agreement would make Future NRG Sdn. Bhd., a Malaysian medical waste treatment company, a wholly owned subsidiary of Bio Green Med Solution, with closing expected in the fourth quarter of 2026.
BGMSREGENXBIO opened an option exchange offer for non-executive employees on June 3, 2026, after stockholders approved it. Stockholders rejected a similar program for executives, and the company's 2025 annual report says the year's $193.9 million net loss and a going-concern doubt sit alongside $240.9 million of cash.
RGNXREGENXBIO started a stock option exchange for non-executive employees on June 3, 2026, after stockholders approved it at the May 29 annual meeting. Stockholders rejected a similar exchange for executives, with 21,021,531 votes against to 14,097,815 for.
RGNXInMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.
INMHealthy Extracts Inc. acquired 100% of Adli Gummies Inc. under an agreement dated May 15, 2026. It issued secured promissory notes of $165,000 and $629,000 and shares equal to approximately 17.76% of its outstanding common stock.
HYEXCumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it.
CPIXCollegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones.
COLLCollegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met.
COLLAurinia said on May 11, 2026 that it completed its acquisition of Kezar Life Sciences. Holders received $6.955 in cash plus one contingent value right per share, after a tender offer in which 5,927,580 Kezar shares, about 80.24% of those outstanding, were validly tendered.
AUPHLisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right.
LSTAAura Biosciences agreed to buy back up to 6,922,870 shares from Matrix Capital at $5.64, the price of an equity offering it announced on May 4, 2026. The buyback comes out of the offering's proceeds, and the company put preliminary cash at $114.7 million as of March 31, 2026.
AURAGyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO.
GYRECandid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.
RLYBThe merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026.
SHPHSenti Biosciences agreed to sell up to $40.0 million of secured convertible notes to an affiliate of its largest stockholder. If the notes are not converted, the company must pay 200% of principal in cash at maturity, and the second tranche depends on a related deal that could pay up to $60.0 million.
SNTIPerrigo (NYSE: PRGO) received €305.6 million at closing and may get up to €27.0 million more over three years. The company says net proceeds will be used primarily to reduce debt.
PRGOAvalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million.
AVTXLigand will pay about $739 million in equity value for XOMA Royalty, plus a contingent value right tied to litigation. The deal needs a XOMA Royalty stockholder vote and is expected to close in the third quarter of 2026.
LGNDOrganon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt.
OGNTelomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met.
TELOGazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close.
OBXFirst Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks.
TRAXAnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP.
ANABShareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.
ANABTRAXThe company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway.
TRAXMeiraGTx also agreed to a one-time $50,000,000 contingent payment and mid-teens royalties starting on or after July 1, 2029. The 8-K also reports an amendment with Hologen.
MGTXMeiraGTx will pay Johnson & Johnson $25 million in cash upfront for bota-vec, a gene therapy whose Phase 3 primary endpoint did not reach statistical significance. The company plans filings in the U.S., EU and Japan, with a potential launch in 2027.
MGTXWave Life Sciences said on April 15, 2026 that its board approved moving the parent company from Singapore to Delaware. Shares would be exchanged one for one, and the company expects the change in mid-2026, subject to shareholder and Singapore High Court approval.
WVESupernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful.
SUPNThe company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years.
NWBOLisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending.
LSTAAn Aurinia subsidiary will buy Kezar Life Sciences for $6.955 in cash per share plus a CVR, but the offer depends on Kezar holding at least $50.0 million of net cash at closing. The deal is expected to close in the second quarter of 2026.
AUPHCyclerion and private Korsana Biosciences signed a merger agreement on April 1, 2026. A concurrent private financing of approximately $380 million is expected to fund Korsana's operations into 2029.
KRSAOramed Pharmaceuticals closed the sale of its Oratech subsidiary to Lifeward Ltd. on March 25, 2026, for 1,250,363 Lifeward ordinary shares, pre-funded warrants, warrants and a 4% revenue share on ReWalk products. The same day it bought $9,000,000 of Lifeward convertible notes, and Lifeward carries a going-concern warning of its own.
ORMPUnder an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license.
SCYXFive buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026.
INDPGilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed.
LKFTNeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.
SPRCNTLXStockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000.
INDPAtrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.
RNAAvidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.
RNASensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients.
FTHNutriband said its board ended the deal after the buyer missed the December 31 closing and stopped paying late fees. The annual report puts the price at $5 million, and only $30,000 in late fees was received.
NTRBThe company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares.
INDVAgenus received $75 million, less certain expenses, for its manufacturing operations, and sold 2,133,333 shares to a Zydus affiliate at $7.50 each. Up to $50 million in further payments depends on orders for its BOT+BAL drug product.
AGENSL Science Holding's F-4 says the blank-check company's trust holds $69,000,000 and that its chairman would control about 58% of the voting power of the combined company. The target's main products include cancer drugs that the filing does not show as approved.
SLBTTivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.
VBIONatera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones.
NTRAOmeros got $240.0 million upfront and may earn up to $510 million in development and approval milestones and $1.3 billion in sales milestones. About $72.6 million retired its credit agreement and the board approved a buyback of up to $100.0 million.
OMERQ32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.
QTTBAKBAAbbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review.
ABTHarrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027.
HROWBristol Myers Squibb amended its cash tender offers for its own notes after the November 17, 2025 early tender deadline. It cut the Pool 1 cap from $4,000,000,000 and raised the Pool 2 cap from $3,000,000,000, and it set early settlement for November 20. Accepted notes will be cancelled and retired.
BMYHoli Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand.
IGCHoli Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain.
IGCGalecto completed its acquisition of Damora Therapeutics on November 10, 2025. A concurrent private placement of Series C preferred stock for approximately $285 million is expected to close November 12.
DMRAOnly $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024.
BFRIA letter agreement dated October 31, 2025 settles all potential milestone payments from Absci's 2021 Totient deal. Former Totient stockholders get about $7.6 million, and Absci gets about $8.7 million.
ABSINova Cell pays by cancelling a net $1,214,864 of debt Calidi owed it, plus $4,785,136 of deferred, contingent consideration. Nova Cell is no longer a subsidiary, and the company expects $0.5 million a year in expense cuts.
CLDIBiofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement.
BFRIAlkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed.
ALKSBioNTech's offer documents register 15,061,575 new ADSs for CureVac shares, with the exchange ratio set by a $5.4641 formula and a collar. The offer opens October 21, 2025, and BioNTech's unaudited first-half figures show a net loss of €802.4 million.
BNTXKeros Therapeutics agreed on October 15, 2025 to buy 10,176,595 shares from two investors for about $181 million at $17.75 each, and plans a tender offer for up to $194 million at the same price. Two directors resigned under the Pontifax agreement, and the company's preliminary cash figure of about $693.5 million is unaudited.
KROSThe repurchases are part of a $375 million capital return program. Keros also plans to share 25% of certain net cash from its Takeda license with stockholders.
KROSAfter the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.
RNAZThe sale closed October 1, 2025 for $88 million in cash, with $8 million held in escrow. Elutia used about $27.8 million to repay SWK Funding debt, and its 2024 annual report carried a going-concern warning after a net loss of $53.9 million.
ELUTElutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027.
ELUTBSXGRID AI's former shareholders would own about 82.5% of Entero's fully diluted common stock, subject to shareholder approval, and could name two directors at closing.
GRDXHalozyme could also owe up to three $50 million milestone payments tied to product regulatory approvals. Closing requires the Hart-Scott-Rodino waiting period to expire or end, and a $36 million reverse termination fee applies in certain cases.
HALOSKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal.
MIRATraws Pharma paid $2,350,000 in cash, in full, for assets tied to a pyrrolidine antiviral compound held by Viriom. The seller's executive chairman is Traws's own chief operating officer, and its 2024 annual report carries a going-concern warning.
TRAWNRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares.
NRXPTraws Pharma paid $2,350,000 in cash for intellectual property and other assets from Viriom, a company tied to its chief operating officer. The board and audit committee approved the deal and called the price fair and reasonable.
TRAWBHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached.
BHCPharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds.
PHVSFibroGen used part of the proceeds to repay about $81 million of Morgan Stanley Tactical Value term loans. Pro forma total equity turns positive only with minority interests counted, while the stockholders' deficit attributable to FibroGen remains.
KYNBPharmaCyte says the money is meant to support TNF's license of a light-based computing platform for cryptocurrency mining. TNF plans to change its name and ticker.
PMCBMedicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.
MDCXCorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029.
CRMDRoyalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.
ZBIORPRXEvofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought.
EVFMHeron's board adopted a Tax Benefit Preservation Plan on August 13, 2025. A holder that reaches 4.99% without board approval would trigger rights, and the company says it had about $1.37 billion of U.S. federal NOLs at December 31, 2024.
HRTXThe plan, effective August 14, 2025, aims to deter any investor or group from reaching 4.99% of the common stock. The release gives no current taxable income, net loss or cash figure.
HRTXBridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025.
BBOTFormer Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds.
PTCTCorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal.
CRMDPTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth.
PTCTQuazar Investment would buy 1.4 million shares and fund trials and infrastructure in the UAE and MENA region. Closing still depends on a capital formation round.
NTHISupernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured.
SUPNAdaptimmune sold its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to a US WorldMeds subsidiary for $55 million in cash at closing, with up to $30 million more on milestones. The $134 million gain is a pro forma estimate built on March 31, 2025 values.
ADAPYThe Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank.
VRXAIkena Oncology, now ImageneBio, closed its merger with Inmagene Biopharmaceuticals on July 25, 2025. It issued contingent value rights to both sets of shareholders, which pay only from proceeds of selected assets, and it took on a transition services deal with a company owned by Inmagene's legacy holders.
IMAA July 2025 corporate overview says the merger closed and that the company has raised $140 million to date. Its lead drug, IMG-007, is in a Phase 2b trial in atopic dermatitis.
IMALantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq.
LNTHThe deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients.
NBPOnconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.
ONCOThe shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure.
BBOTBBIODenali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.
SMNRRecursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.
RLYBRallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.
RLYBThe July 1, 2025 closing included a one-for-ten reverse stock split, a name change and royalty sales to Nomis RoyaltyVest, Ligand and Madison Royalty LLC. The shares were to trade as PTHS.
PTHSThe sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer.
ABEOChannel Therapeutics will cut its share count from about 6,485,007 to about 648,501 in a 10-for-one reverse split before its merger with LNHC and a roughly $50 million raise led by Murchinson. The company says the split is meant to help it meet NYSE American initial listing requirements.
PTHSInmagene dosed the first patient in its ADAPTIVE trial of IMG-007 in atopic dermatitis, with topline results expected in the fourth quarter of 2026. Ikena filed the news as merger material.
IMATuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.
HURAEach Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.
HURAAntev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.
MDCXImpact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals.
IBOThe combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval.
IBOOrthoCellix's stockholder and the concurrent financing investors are expected to own about 90% of the combined company, with Carisma holders at about 10%. The deal is all stock and needs approval from both companies' stockholders.
OCGNCARMEnzon, which calls itself a public company acquisition vehicle, agreed on June 20, 2025 to merge with Viskase in an all-stock deal. Viskase holders would own about 84.1% of the combined company, and Enzon common holders about 2.06%. The 8-K and release give no Viskase revenue, debt or earnings.
VISKCrescent Biopharma completed its merger with GlycoMimetics, and the combined company began trading as CBIO on June 16, 2025. The $200 million financing includes $37.5 million of converted notes. GlycoMimetics's own 2024 10-K had raised going-concern doubt.
CBIOSalarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.
DCOYAytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million.
AYTUAytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales.
AYTUCheckpoint Therapeutics became a wholly owned Sun Pharma subsidiary on May 30, 2025. Fortress may also get up to $4.8 million through CVRs and a 2.5% royalty on certain net sales.
FBIOFortress Biotech says it will receive about $28.0 million in cash from the sale of Checkpoint Therapeutics to Sun Pharma, with up to $4.8 million more if a milestone is met. The gain on deconsolidation is an accounting figure, and pro forma cash is lower than reported.
FBIOAlto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028.
ANROAlumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board.
ALMSThe closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap.
ALMSRoyalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association.
RPRXPhytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets.
PTIXPulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025.
PULMPulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing.
PULMJade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28.
JBIOAerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company.
JBIOAerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes.
JBIOAnnJi will pay Avenue $2.0 million over 90 days, plus possible milestones and a 1.75% royalty.
ATXITriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change.
TLSIJazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz.
JAZZSemnur signed Amendment No. 1 on April 16, 2025, covering Denali's move from Nasdaq to OTC quotation and extending its deadlines.
SCLXCara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported.
TVRDOS Therapies says the purchase adds three clinical-stage and eight preclinical listeria-based cancer immunotherapy candidates, but the release gives neither the price nor the terms.
OSTXCoherus received $483.4 million in cash at the April 11, 2025 closing and says it has a $250 million post-close cash balance. It is eligible for milestone payments of up to $75 million.
CHRSCoherus can earn up to $75 million more in sales milestones and says it has $250 million in cash after closing, enough to fund work into 2027.
CHRSAmendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision.
PULMPulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed.
PULMZevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025.
ZVRALantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible.
LNTHCara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000.
TVRDProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent.
PROKFibroGen, now Kyntra Bio, and Fortis Therapeutics amended their evaluation agreement and option and merger agreement, moving the option exercise deadline.
KYNBKAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc.
WHWKThe buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.
WHWKEntero Therapeutics, now GridAI Technologies, signed a rescission agreement with all former ImmunogenX shareholders. It still needs shareholder approval on or before June 30, 2025.
GRDXBausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan.
BHCThe combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis.
KLRSPre-merger Kalaris holders own about 74.47% of the combined company. Cash of about $100 million is expected to last into the fourth quarter of 2026.
KLRSPliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026.
PLRXPliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial.
PLRXAt a March 12, 2025 special meeting, AlloVir holders approved the share issuance and change of control under Nasdaq rules, and a stock plan increase. The merger is expected to close as soon as practicable.
KLRSAlloVir holders backed all proposals at a special meeting on March 12, 2025. The combined company is expected to be renamed Kalaris Therapeutics and trade on Nasdaq as KLRS.
KLRSAnika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles.
ANIKThe deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.
ANIKCheckpoint Therapeutics, the majority-controlled unit of Fortress Biotech, agreed to be bought by Sun Pharma for $4.10 in cash per share plus a contingent value right of up to $0.70. Fortress has agreed to vote in favor and will receive a 2.5% royalty.
FBIOJazz Pharmaceuticals agreed to buy Chimerix for $8.55 a share in cash, about $935 million in total, through a tender offer. The main asset, dordaviprone, is still awaiting an FDA decision, and Chimerix owes Jazz a $35 million fee in some cases if it accepts a rival offer.
JAZZAerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO.
JBIOMustang Bio received the $1.0 million purchase price from escrow on February 25, 2025. It expects about $2.0 million in cash savings on the lease over the next 24 months and has moved its headquarters to Waltham.
MBIOCrescent Biopharma said on February 24, 2025 that it still expects its reverse merger with GlycoMimetics to close in the second quarter of 2025. The merger filing says the deal depends on a financing transaction and on GlycoMimetics stockholder approval.
CBIOThe company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.
MBIOThe drug-delivery company is acquiring an AI solar analytics platform from BladeRanger Ltd. BladeRanger would receive 178,769 ordinary shares plus four sets of warrants, and the release gives no price or valuation for the business.
PRFXACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated.
ALMSACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances.
ALMSBaxter completed the sale of its Kidney Care business on January 31, 2025 and received about $3.71 billion in net, pre-tax cash at closing, against a $3.80 billion price set at signing. The price is still subject to post-closing adjustments, and executive Chris Toth stepped down on the closing date.
BAXAadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing.
WHWKCoherus could also earn two $37.5 million payments if UDENYCA sales hit set targets. The board unanimously recommends a vote for the sale.
CHRSRenovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.
LNAIInvestor David Lazar agreed to subscribe for $3.1 million of convertible preferred stock and become interim chief executive. A separate warrant exchange would issue 24,844,725 common shares and pay $1,100,000 in cash. The Series D closing and the warrant exchange need stockholder approval, and the Nasdaq deadline is February 6, 2025.
BGMSEton bought the Wilson Disease treatment on December 31, 2024 for $7.0 million at closing plus $0.2 million for inventory. It will also pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of its first U.S. sale.
ETONThe lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.
ASBPThe unit held the legacy AgeX assets. Juvenescence, Serina's largest holder, paid a nominal cash amount on top of assuming the secured debt.
SERCara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash.
TVRDThe Supreme Court of New South Wales approved the scheme of arrangement. Neuphoria shares are expected to start trading on Nasdaq as NEUP on December 24, 2024.
NEUPNektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024.
NKTRThe letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.
HURAAbout 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency.
AKTXGeron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate.
GERNPalvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny.
PVLARenexxion holders would own about 72.2% of the combined company under the initial ratio. The companies aim to sign a definitive agreement by December 31, 2024.
MMTXLyell adds IMPT-314, a CAR T-cell candidate, through the ImmPACT Bio deal. The release gives no purchase price and no cash balance, and says cash will fund operations into 2027.
LYELImmunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.
IMNMBellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings.
OSRH
aibio